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Abstract
Background: The incidence of infectious disease caused by nontuberculous mycobacteria is increasing worldwide.
Pulmonary Mycobacterium avium complex (MAC) disease is difficult to treat with chemotherapy, and its mechanism
of infection, infection route, disease onset, and severity remain unknown. Ficolins are oligomeric defense lectins. L-
ficolin plays an important role in innate immunity. This study’s aim was to identify L-ficolin’s role in patients with
pulmonary MAC disease.
Methods: Between April 2011 and September 2017, 61 Japanese patients with pulmonary MAC disease were seen
at our hospital. A control group, comprising 30 healthy individuals, without respiratory disease were enrolled in our
study. The relationship between serum L-ficolin levels and disease severity was assessed, and L-ficolin’s antibacterial
role was examined.
Results: Serum L-ficolin levels were significantly lower in patients with pulmonary MAC disease than in healthy subjects
(1.69 ± 1.27 μg/ml vs. 3.96 ± 1.42 μg/ml; p < 0.001). The cut-off value, based on receiver operating characteristic (ROC)
analysis results, was 2.48 μg/ml (area under the curve (AUC) 0.90, sensitivity and specificity 83.6 and 86.7%, respectively).
Serum L-ficolin levels were significantly lower in the patients with nodular bronchiectatic type disease compared with
the patients with fibrocavitary type disease and were lower in the high-resolution computed tomography high-scoring
group compared with low-scoring group. An in vitro analysis showed that purified recombinant L-ficolin bound to M.
avium and its major cell wall component, lipoarabinomannan, in a concentration-dependent manner. In addition,
recombinant L-ficolin suppressed M. avium growth in a concentration-dependent manner.
Conclusions: Insufficient serum L-ficolin is associated with disease progression in pulmonary MAC disease, and
the level of serum L-ficolin is a possible biomarker.
Trial registration: This study is registered with UMIN (UMIN000022392).
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Background
Nontuberculous mycobacteria (NTM) have been seen as
environmental organisms of limited clinical relevance,
overshadowed by the more aggressive Mycobacterium
tuberculosis. However, chronic pulmonary disease,
caused by NTM, is increasing in Japan because of an
aging population. In 2014, the NTM incidence rate in
Japan was 14.7 per 100,000 based on national surveil-
lance data [1]. Mycobacterium avium complex (MAC)
organisms are the major causative bacteria of NTM
infection in patients who do not have cystic fibrosis;
these organisms are difficult to treat with chemotherapy.
Pulmonary MAC disease is responsible for approxi-
mately 80% of the NTM cases in Japan. A systematic re-
view indicated a high mortality rate among patients with
pulmonary MAC [2].
Older age and female sex are well-known risk factors
for NTM infection. Having a low body mass index
(BMI) also appears to be a risk factor for NTM infection;
higher BMI has a protective effect. Substantial hetero-
geneity was found among male patients, with the pres-
ence of cavity disease and high comorbidity levels
predicting worse outcomes. In terms of molecular path-
ology, the adipokines leptin and adiponectin may be
responsible for the presence of NTM disease [3–6].
Severe vitamin D deficiency also appears to be associated
with NTM disease [7].
Innate immune molecules can suppress the early
stages of infection via mechanisms mediated by many
different recognition systems and effectors, including the
complement system. Pulmonary surfactant protein (SP-
)A, SP-D, mannose-binding lectin (MBL), and ficolins
are all types of complement lectins, capable of recogniz-
ing microbial carbohydrates and activating the lectin
complement pathway via a mechanism similar to that of
the classical pathway.
Ficolins are oligomeric defense, proteins assembled
from collagen-like stalks and fibrinogen-like domains
that can sense danger signals, such as pathogens and
apoptotic cells. Three members of the ficolin family have
been identified and characterized in humans: M-ficolin
(ficolin-1), L-ficolin (ficolin-2), and H-ficolin (ficolin-3,
or Hakata antigen) [8–10]. Human L-ficolin and H-
ficolin are mainly expressed in the liver and present in
the circulation as serum lectins.
Human L-ficolin has lectin-like activity for N-
acetylglucosamine (GlcNAc), lipopolysaccharides, 1,3-
beta-D-glucan, lipoteichoic acid, and various acetylated
compounds [11–13].
L-ficolin’s fibrinogen-like domain forms a globular
structure, similar to the carbohydrate-recognition do-
mains of MBL, SP-A, and SP-D, and binds to sugar struc-
tures. Ficolins also show opsonic activity via the binding
of their collagen-like domain to macrophages [14].
L-ficolin is said to specifically bind to some clinically
important microorganisms (group B streptococcus,
Streptococcus pneumoniae, and M. tuberculosis), act as
an opsonin, and promote microbe elimination through
the elicitation of phagocytosis or the activation of the
lectin pathway of the complement system in in vitro
tests [15–19].
So far, we have clarified that SP-A and SP-D play
important roles in MAC infections [20, 21]. Conversely,
L-ficolin’s role in MAC infections remains completely un-
known. This study’s aim was to identify L-ficolin’s role in
MAC infections. Our findings support the notion that L-
ficolin plays a role in the pathogenesis of MAC infections
and suggest that L-ficolin may be a novel biomarker of
MAC infection as well as a therapeutic target.
Methods
Participants
This case-control study was conducted at a single center,
the Sapporo Medical University Hospital, Sapporo, Japan,
between April 2011 and September 2017. The hospital’s
ethics board approved this study (approval number 272–
168), and all participants gave written informed consent.
Patients with NTM infection were included if they
visited or were admitted to the hospital, and NTM infec-
tion was diagnosed based on the 2007 diagnostic criteria
of the American Thoracic Society/Infectious Disease
Society of America [22]. Exclusion criteria were the
patient’s inability to give informed consent and an NTM
infection not caused by MAC. The control group partici-
pants included healthy volunteers who showed no evi-
dence of respiratory disease following a Shihoro-cho
health check.
Measurement of serum L-ficolin concentration
Serum L-ficolin levels were measured using an ELISA
Kit (Hycult Biotech Inc., PA, USA) according to the
manufacturer’s instructions.
High-resolution computed tomography (HRCT) scoring
Within 3 months of entry into the study, thin slice (1
mm) HRCT images were obtained from the participants
at 10 mm intervals from the lung apex to the base dur-
ing suspended full inspiration with the participant in the
supine position. All HRCT data were reconstructed
using a high spatial frequency algorithm and displayed
on the lung parenchymal window (level, − 700 Houns-
field units (HU); width, 1500 HU). The HRCT images
were scored for the severity and the extent of the
pulmonary MAC infection using the modified scoring
system of Fowler et al. [23]. The summary of the HRCT
scoring of the whole lung is shown in Additional file 1:
Table S1A. To identify the differences in serum L-ficolin
levels by severity of MAC disease, MAC patients were
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separated into two groups according to the HRCT score.
The HRCT low-score group was ≤6 and the high-score
group was ≥7.
Binding of L-ficolin to M. avium
MycoBroth and 7H11-C agar plates were purchased
from Kyokuto Pharmaceutical (Tokyo, Japan). M. avium
cultures were purchased from ATCC (No. 700898). This
strain was the M. avium subspecies hominissuis, which
is a major human MAC subtype in Japan [24]. Another
M. avium strain was clinically isolated from the sputum
of an infected patient. The bacteria were cultured in
MycoBroth and suspended in phosphate-buffered saline.
The concentration of the bacterial suspension was deter-
mined by measuring the absorbance at 600 nm.
A suspension of UV-killed M. avium was coated onto
microtiter wells and then dried. After the wells were
washed, the bacteria were incubated with L-ficolin at
37 °C for 1 h. The wells were washed and then incubated
with anti-L-ficolin antibodies and secondary antibodies
at 37 °C for 1 h. The binding of L-ficolin to M. avium
was detected by measuring the absorbance at 492 nm.
Surface plasmon resonance analysis
Sonicated lipoarabinomannan (LAM) was immobilized
on an HPA sensor chip of the Biacore 3000 system (Bia-
core, Uppsala, Sweden) according to the manufacturer’s
specifications. L-ficolin was injected at a flow rate of
30 μl/min. Sensorgrams of the interactions obtained
using various concentrations of L-ficolin were analyzed
using the BIAevaluation program.
Growth inhibition assay
M. avium (2000 CFU) was cultured in MycoBroth at
37 °C for 96 h in the presence or absence of L-ficolin or
other lectins. At 0, 8, 24, 48, and 96 h an aliquot of the
culture was withdrawn and spread onto a 7H11-C agar
plate. The plates were incubated at 37 °C for 48 h, and
the number of colonies on the plates was then counted.
Statistical analysis
All statistical analyses were performed using JMP 13.0
(SAS Institute, Cary, NC, USA) and GraphPad Prism v7
software (GraphPad, Inc., San Diego, CA, USA). Stu-
dent’s t-test or one-way analysis of variance (ANOVA)
with post-hoc Tukey test were used to analyze continu-
ous parametric data.
For all analyses, a p value < 0.05 was considered statis-
tically significant.
Results
This study included 61 patients with pulmonary MAC
and 30 healthy volunteers in the control group. The par-
ticipants’ characteristics are shown in Table 1.
Patients with MAC were aged 70.9 ± 8.9 years on aver-
age and included 11 males (18.0%) and 50 females
(82.0%); this was different from the control group but
comparable to Japanese MAC surveillance data [1]. The
MAC patients’ average BMI was 20.3 ± 3.0 kg/m2, which
was lower than that for individuals in the control group.
Among the MAC patients, 43 (70.5%) had never
smoked. Although white blood cell (WBC) counts were
not significantly elevated, C-reactive protein (CRP) and
serum SP-A, and SP-D levels were significantly higher in
patients with MAC compared with those in the control
group, suggesting an inflammatory reaction in the lungs
of patients with pulmonary MAC disease.
The bacteriologically detected species of NTM were
M. avium (n = 47, 77.0%), M. intracellulare (n = 8,
13.1%), and mixed infections of MAC and other myco-
bacteria (n = 6, 9.8%) (Table 2). Anti-MAC antibodies
were detected in 43 MAC patients (70.5%). The positivity
rate of anti-MAC antibodies in our study was similar to
that of Japanese MAC patients described in a previous
study [25]. Twelve participants (19.7%) were undergo-
ing treatment with immunosuppressants because of
comorbidity. Four patients (6.6%) tested positive by
interferon-gamma releasing assay (IGRA). Combination
chemotherapy was administered to 28 MAC patients
(45.9%) while they were participating in this study.
Comparison between the MAC and the control groups
The serum L-ficolin level was quantified using an ELISA
kit. Serum L-ficolin was 1.69 ± 1.27 μg/ml in MAC pa-
tients compared with 3.96 ± 1.42 μg/ml in control subjects
(Fig. 1a, p < 0.001). A receiver operating characteristic
(ROC) curve constructed between the MAC patients and
healthy control participants revealed an area under the
curve (AUC) of 0.90, a sensitivity of 83.6%, and a specifi-
city of 86.7% when the cut-off for serum L-ficolin was set
at 2.48 μg/ml (Fig. 1b).
Radiographic disease extent and L-ficolin
From the HRCT findings in MAC patients, the mean
serum L-ficolin level in those patients with fibrocavitary
type (FC type) was 3.09 ± 2.35 μg/ml, similar to the level
seen in the healthy control group (Fig. 2a). However, the
mean serum L-ficolin level in the patients with the
nodular bronchiectatic type (NB type) was 1.51 ±
0.89 μg/ml, significantly lower than the level in the
patients with the FC type (p < 0.01). Compared with
patients with the FC type, the patients with the NB type
also showed lower levels of other parameters, such as
WBC, CRP, albumin, and SP-A, indicating that the NB
type could elicit a lower inflammatory response (Table 3).
To evaluate the disease progression of pulmonary MAC,
we scored the HRCT findings using a scoring system
(Additional file 1: Table S1A). The average HRCT score
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was 6.25 ± 3.30 (Additional file 1: Table S1B). Serum L-
ficolin levels in the high-score group were lower than
those in the low-score group (Fig. 2b, p < 0.05).
Direct interaction between M. avium and L-ficolin
We first confirmed the binding of recombinant L-ficolin
to M. avium coated onto microtiter wells. L-ficolin
bound to M. avium in a concentration-dependent man-
ner (Fig. 3a). To determine whether the ligand for L-
ficolin was LAM, surface plasmon resonance sensor
analysis was performed (Fig. 3b). The passage of L-
ficolin at various concentrations over LAM immobilized
on a sensor chip yielded an association rate constant, ka,
of 2.41 × 105M− 1 s− 1 and a dissociation rate constant,
kd, of 2.16 × 10− 4 s− 1, giving a subsequent dissociation
constant, KD (kd/ka), of 8.96 × 10− 10 M. These results
indicate that L-ficolin binds to M. avium and that the
ligand targeted by L-ficolin might be LAM.
Complement lectins inhibit the growth of M. avium
We examined whether L-ficolin affected the growth of
M. avium in vitro (Fig. 4a). SP-A and SP-D were used as
positive and negative controls, respectively. Cultures
were started at 2000 CFU/ml, and no significant differ-
ences were observed among the samples between hours
0 and 24. However, L-ficolin clearly inhibited M. avium
growth after 48 h compared with the control and SP-D
samples (Fig. 4b). Furthermore, L-ficolin 0.5–20 μg/ml
inhibited M. avium growth after 48 h in a concentration-
dependent manner, and growth under conditions with
20 μg/ml L-ficolin was significantly suppressed compared
with the untreated control growth (Fig. 4c).
Discussion
This is the first study to investigate L-ficolin serum
levels in relation to clinical pulmonary MAC disease.
We found a significant difference in serum L-ficolin
levels between MAC patients and control subjects. Also,
serum L-ficolin levels were found to be related to the
severity of MAC disease. Additionally, it was revealed
that L-ficolin bound directly to M. avium and inhibited
its growth, suggesting that L-ficolin activity worked as a
host defense against M. avium infection.
MAC patients with cavity type disease have higher
mortality rates than those without cavity type disease
[25]. From the data obtained by HRCT analysis of MAC
types, the FC type exhibits a stronger inflammatory re-
sponse than the NB type. The characteristics of patients
with NB type MAC also had less inflammation.
Serum L-ficolin levels in MAC patients showed high
sensitivity and specificity (83.6 and 86.7%, respectively),
and indicated a negative correlation with the extent of the
disease. Kitada et al. proved the usefulness of ELISA kits
in diagnosing MAC [26]. Higher human serum antibody
Table 2 The status of patients with MAC (n = 61)







HRCT findings NB type/NB + FC type/FC type 47/5/7
MAC-Ab (antibody
titer)













Data are presented as the number of patients
Abbreviations: HRCT high-resolution computed tomography, NB type nodular
bronchiectatic type, FC type fibrocavitary type, IGRA interferon-gamma
releasing assay













Age (years) 45.7 ±
15.5
70.9 ± 8.9 p < 0.001





Sex (male/female) 23/7 11/50 p < 0.001
History of smoking (never / < 20
packs / > 20 packs)
19/10/1 43/11/7 –
BMI (kg/m2) 23.9 ± 3.6 20.3 ± 3.0 p < 0.001

























Data are presented as mean ± SD. p values were calculated using the
Student’s t-test
Abbreviations BMI body mass index, WBC white blood cells, CRP C-reactive
protein, Alb albumin, SP-A surfactant protein A, SP-D surfactant protein D
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levels to glycopeptidolipid core antigen showed high sensi-
tivity and specificity (84.3 and 100%, respectively), and
revealed a positive correlation with the extent of disease.
Low serum L-ficolin levels are associated with several lung
diseases. The serum L-ficolin levels of patients with
pulmonary tuberculosis has been shown to be lower than
that of healthy individuals [27]. L-ficolin can bind to M.
tuberculosis and defend against M. tuberculosis infection
by activating innate immune responses. Insufficient serum
L-ficolin levels have been seen in patients with severe
community-acquired pneumonia [28]. Patients with bron-
chiectasis also have very low L-ficolin levels [29, 30]. In-
sufficient L-ficolin is not specific for pulmonary MAC, but
suggests existing chronic or infectious lung diseases.
Fig. 2 a Differences in serum L-ficolin levels by type of MAC disease. NB type, nodular bronchiectatic type; FC type, fibrocavitary type. Lines
express the mean ± SD. One-way ANOVA with post-hoc Tukey test, ** p < 0.01. b Differences in serum L-ficolin levels by severity of MAC disease.
MAC patients were separated into two groups by HRCT scoring. The HRCT low-score group was ≤6 and the high-score group was ≥7. Lines
express the mean ± SD. Student’s t-test, * p < 0.05
Fig. 1 a Difference in serum L-ficolin levels between the Mycobacterium avium complex (MAC) patients and the healthy participants. Lines express the
mean ± SD. Student’s t-test, *** p < 0.001. b Receiver operating characteristic curve constructed between MAC patients and healthy participants
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According to the criteria for MAC, single and mixed
mycobacterial infections were included, as shown in
Table 2. When we exclude the four subjects with mixed
infections, 57 cases of MAC also had significantly low L-
ficolin levels (1.65 ± 1.28 μg/ml) and similar correlations
of L-ficolin with the disease extent (data not shown).
Ficolins bind to a variety of ligands on various patho-
gens. L-ficolin’s fibrinogen-like domain forms a globular
structure, similar to the carbohydrate-recognition do-
mains of MBL, SP-A, and SP-D, and binds to sugar
structures. According to our binding analysis, L-ficolin’s
binding to M. avium was specific but not completely
dissociated by EDTA (data not shown). Previous reports
indicated that the ligand for SP-D is LAM [20]. Our
surface plasmon resonance sensor analysis indicated that
L-ficolin attached to LAM; however, LAM did not com-
pletely inhibit L-ficolin’s binding to M. avium when
using ELISA methods (data not shown). As a result, we
could not determine if there were one-to-one binding
sites. Additional experiments to identify the ligand for
L-ficolin will be necessary in the future.
Previous studies have shown that complement lectins
inhibit the growth of mycobacteria. Ariki et al. indicated
that SP-A, but not SP-D, strongly inhibited M. avium
growth without complement activation [20]. We re-
vealed that human L-ficolin also directly inhibited M.
avium growth. L-ficolin and SP-A form a bouquet-like
structure consisting of six trimeric subunits. SP-D ex-
hibits a cruciform structure consisting of four trimeric
subunits. This structural difference causes distinct bio-
logical functions. Although L-ficolin was reported to
bind to some microorganisms and act as an opsonin,
direct inhibition of growth has not been reported. This
novel effect of L-ficolin may play an important role in
innate immunity in the pulmonary environment, espe-
cially via synergistic effects with SP-A.
There are some limitations to this study. First, the ages
and sexes of the MAC group did not match those in the
control group. Because the control subjects in this study
were collected from health check individuals in a
hospital, we could not match the status. Since previous
reports indicated that the serum concentration of L-
ficolin was not affected by age or sex, this mismatch is
unlikely to have affected the study’s results [31–33]. We
confirmed other 12 samples of age (70.4 ± 5.1 y.o.) and
sex (F:M = 10:2) matched samples (data not shown).
Mean serum L-ficolin levels were 3.60 ± 0.58 μg/ml,
which was no significant difference with this study’s 30
control subjects. L-ficolin levels were not affected by age
and sex. Second, the measurement of L-ficolin was taken
at a single point in MAC patients; 45.9% of the MAC
patients were under treatment or post-treatment. It was
not determined whether treatment could change the
serum L-ficolin levels. Third, we could not determine
whether reduced serum L-ficolin resulted in MAC
infection or whether MAC-infected patients lost serum
L-ficolin. Several reports indicated that FCN2 gene
Table 3 HRCT types and laboratory data for patients with MAC
NB type
(n = 49)





L-Ficolin (μg/ml) 1.51 ± 0.89 1.53 ± 1.60 3.09 ± 2.35 p = 0.006
Age (years) 70.7 ± 8.2 72.0 ± 5.1 71.6 ± 15.6 p = 0.934
BMI (kg/m2) 20.5 ± 3.0 17.7 ± 1.9 21.0 ± 3.6 p = 0.120
WBC (/μl) 5557 ± 1516 6680 ± 1654 7157 ± 2036 p = 0.026
CRP (mg/dl) 0.16 ± 0.23 0.38 ± 0.61 1.27 ± 1.09 p < 0.001
Alb (g/dl) 3.95 ± 0.29 3.60 ± 0.16 3.47 ± 0.50 p = 0.001
SP-A (ng/ml) 33.6 ± 14.2 50.6 ± 20.0 51.3 ± 19.0 p = 0.003
SP-D (ng/ml) 109.5 ± 74.9 186.7 ± 118.3 124.7 ± 77.4 p = 0.119
Data are presented as mean ± SD. p values were calculated using the one-way
ANOVA with post-hoc Tukey test
Fig. 3 The binding of recombinant human L-ficolin to M. avium. a The indicated concentrations of recombinant L-ficolin were incubated with
clinically isolated M. avium coated onto microtiter wells. Bound L-ficolin was detected at OD 492 nm. The data show the mean ± SD of three
independent experiments. b The binding parameters of recombinant L-ficolin with M. avium were determined by surface plasmon resonance analysis.
Sensorgrams for the binding of recombinant L-ficolin to M. avium immobilized on a sensor chip were overlaid at various concentrations of L-ficolin
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polymorphisms result in insufficient serum L-ficolin [34,
35]. Single-nucleotide polymorphisms in the promoter re-
gion and in exon-8 have significant effects on measured
serum levels. Considering this, insufficient L-ficolin could
be a risk factor for pulmonary MAC disease.
Conclusions
In conclusion, insufficient serum L-ficolin is associated
with disease presence and extent of pulmonary MAC
disease. Serum levels of L-ficolin are a possible bio-
marker of pulmonary MAC disease.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s12931-019-1185-9.
Additional file 1:Table S1A. is the summary of HRCT scoring system of
the whole lung. To evaluate the disease progression of pulmonary MAC,
we scored the HRCT findings. Each score was from 0 to 3 and the score
of seven categories were totaled. The average HRCT score of each
category was shown in table S1B. The average of total was 6.25 ± 3.30
indicating the patients’ severity were mild to moderate on the HRCT
criteria.
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BMI: Body mass index; FC type: Fibrocavitary type; HRCT: High-resolution
computed tomography; HU: Hounsfield units; LAM: Lipoarabinomannan;
MAC: Mycobacterium avium complex; MBL: Mannose-binding lectin;; NB
type: Nodular bronchiectatic type; NTM: Nontuberculous mycobacteria; ROC
curve: Receiver operating characteristic curve; SP-A and D: Surfactant
proteins A and D
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